| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
in Relation to Cell Type, Malignancy, and Differentiation in Ovary, Uterus, and Cervix1
Departments of Biochemistry and Molecular Biology [M. W., M. R.] and Pathology [W. G.], Medical College of Ohio, Toledo, Ohio 43614-5804
The folate receptor (FR) type 
is known to be frequently overexpressed in ovarian cancer and is the target for a number of novel experimental cancer therapies. The relative levels of FR expression among specific cell types and its relationship to malignant transformation have not been adequately established because of several inherent limitations of the immunocytochemical approaches used previously. We used a quantitative in situ hybridization method to examine the expression of the mRNAs for the known isoforms of FR in paraffin-embedded tissue sections of multiple samples of the various subtypes of ovarian, uterine, and cervical cancers. Benign lesions, as well as the various normal cell types in the ovary, the uterus, and the cervix, were examined similarly. FR mRNA levels were quantitated relative to the transcript levels for ß-actin using NIH Image 1.57 computer software. The results show that the ovary, the uterus, and the cervix present different patterns of FR regulation in differentiation and in malignancy. In the ovary, benign differentiation of the germinal epithelium into mucinous or serous tumors or malignant transformation into mucinous tumors is associated with down-regulation of FR-, whereas FR- expression is retained in malignant lesions of serous and endometrioid differentiation. In contrast, malignant transformation of the glandular epithelial cells of the uterine endometrium is associated with de novo expression of FR-. Heterogeneity in FR expression within malignant ovarian and uterine tumors is related to differentiation. In contrast to the uterus, malignant transformation of glandular epithelial cells in the cervix may frequently result in down-regulation of FR-. These results shed new light for the identification of malignancies suitable for FR-mediated therapies and for prognostic/diagnostic applications of FR. They also provide a phenomenological basis for molecular studies of FR regulation in malignant cells.
This article has been cited by other articles:
|
|
 |
|
  A. Yamada, Y. Taniguchi, K. Kawano, T. Honda, Y. Hattori, and Y. Maitani Design of Folate-Linked Liposomal Doxorubicin to its Antitumor Effect in Mice Clin. Cancer Res., December 15, 2008; 14(24): 8161 - 8168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. A. Matulonis, N. S. Horowitz, S. M. Campos, H. Lee, J. Lee, C. N. Krasner, S. Berlin, M. R. Roche, L. R. Duska, L. Pereira, et al. Phase II Study of Carboplatin and Pemetrexed for the Treatment of Platinum-Sensitive Recurrent Ovarian Cancer J. Clin. Oncol., December 10, 2008; 26(35): 5761 - 5766. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Iwakiri, M. Sonobe, S. Nagai, T. Hirata, H. Wada, and R. Miyahara Expression Status of Folate Receptor {alpha} Is Significantly Correlated with Prognosis in Non-Small-Cell Lung Cancers Ann. Surg. Oncol., March 1, 2008; 15(3): 889 - 899. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chattopadhyay, R. G. Moran, and I. D. Goldman Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications Mol. Cancer Ther., February 1, 2007; 6(2): 404 - 417. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hasegawa, T. Nakamura, M. Harvey, Y. Ikeda, A. Oberg, M. Figini, S. Canevari, L. C. Hartmann, and K.-W. Peng The Use of a Tropism-Modified Measles Virus in Folate Receptor-Targeted Virotherapy of Ovarian Cancer. Clin. Cancer Res., October 15, 2006; 12(20): 6170 - 6178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Tworoger, J. L. Hecht, E. Giovannucci, and S. E. Hankinson Intake of Folate and Related Nutrients in Relation to Risk of Epithelial Ovarian Cancer Am. J. Epidemiol., June 15, 2006; 163(12): 1101 - 1111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Kelemen, T. A. Sellers, G. L. Keeney, and W. L. Lingle Multivitamin and Alcohol Intake and Folate Receptor {alpha} Expression in Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., September 1, 2005; 14(9): 2168 - 2172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tran, A. Shatnawi, X. Zheng, K. M.M. Kelley, and M. Ratnam Enhancement of Folate Receptor {alpha} Expression in Tumor Cells Through the Glucocorticoid Receptor: A Promising Means to Improved Tumor Detection and Targeting Cancer Res., May 15, 2005; 65(10): 4431 - 4441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shiokawa, Y. Hattori, K. Kawano, Y. Ohguchi, H. Kawakami, K. Toma, and Y. Maitani Effect of Polyethylene Glycol Linker Chain Length of Folate-Linked Microemulsions Loading Aclacinomycin A on Targeting Ability and Antitumor Effect In vitro and In vivo Clin. Cancer Res., March 1, 2005; 11(5): 2018 - 2025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Jhaveri, A. S. Rait, K.-N. Chung, J. B. Trepel, and E. H. Chang Antisense oligonucleotides targeted to the human {alpha} folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment Mol. Cancer Ther., December 1, 2004; 3(12): 1505 - 1512. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Theti and A. L. Jackman The Role of {alpha}-Folate Receptor-Mediated Transport in the Antitumor Activity of Antifolate Drugs Clin. Cancer Res., February 1, 2004; 10(3): 1080 - 1089. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M R Pillai, P Chacko, L A Kesari, P G Jayaprakash, H N Jayaram, and A C Antony Expression of folate receptors and heterogeneous nuclear ribonucleoprotein E1 in women with human papillomavirus mediated transformation of cervical tissue to cancer J. Clin. Pathol., August 1, 2003; 56(8): 569 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Theti, V. Bavetsias, L. A. Skelton, J. Titley, D. Gibbs, G. Jansen, and A. L. Jackman Selective Delivery of CB300638, a Cyclopenta[g]quinazoline-based Thymidylate Synthase Inhibitor into Human Tumor Cell Lines Overexpressing the {alpha}-Isoform of the Folate Receptor Cancer Res., July 1, 2003; 63(13): 3612 - 3618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. M. Kelley, B. G. Rowan, and M. Ratnam Modulation of the Folate Receptor {alpha} Gene by the Estrogen Receptor: Mechanism and Implications in Tumor Targeting Cancer Res., June 1, 2003; 63(11): 2820 - 2828. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hao, H. Qi, and M. Ratnam Modulation of the folate receptor type {beta} gene by coordinate actions of retinoic acid receptors at activator Sp1/ets and repressor AP-1 sites Blood, June 1, 2003; 101(11): 4551 - 4560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zheng, K. Kelley, H. Elnakat, W. Yan, T. Dorn, and M. Ratnam mRNA Instability in the Nucleus Due to a Novel Open Reading Frame Element Is a Major Determinant of the Narrow Tissue Specificity of Folate Receptor {alpha} Mol. Cell. Biol., March 15, 2003; 23(6): 2202 - 2212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Q. Pan, X. Zheng, G. Shi, H. Wang, M. Ratnam, and R. J. Lee Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta -targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid Blood, June 28, 2002; 100(2): 594 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-O. Evans, A. N. Young, M. R. Brown, D. J. Brat, John. S. Parks, A. S. Neish, and N. M. Oyesiku Novel Patterns of Gene Expression in Pituitary Adenomas Identified by Complementary Deoxyribonucleic Acid Microarrays and Quantitative Reverse Transcription-Polymerase Chain Reaction J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3097 - 3107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bueno, K. Appasani, H. Mercer, S. Lester, and D. Sugarbaker The {{alpha}} folate receptor is highly activated in malignant pleural mesothelioma J. Thorac. Cardiovasc. Surg., February 1, 2001; 121(2): 0225 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Wang, X. Zheng, F. G. Behm, and M. Ratnam Differentiation-independent retinoid induction of folate receptor type beta , a potential tumor target in myeloid leukemia Blood, November 15, 2000; 96(10): 3529 - 3536. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
